Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | Mr. Michael A. MarksCFO & Exec. VP | -3,34k | 0,00 | Other Disposition | - | 73,08k | -4,37% |
| 2026-02-13 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -5,00k | 1,51M | Derivative Exercise and Sale | 236,61 - 540,29 | 10,99k | - |
| 2026-02-11 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -4,00k | 2,02M | Vente | 505,00 | 44,38k | -8,27% |
| 2026-02-10 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -1,03k | 519,12k | Sale to Issuer | 502,05 | 44,38k | -2,28% |
| 2026-02-10 | Ms. Erica L. RossittoSenior VP & Chief Nurse Executive | -418,00 | 209,86k | Sale to Issuer | 502,05 | 10,41k | -3,86% |
| 2026-02-10 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -3,01k | 1,51M | Sale to Issuer | 502,05 | 10,99k | -21,48% |
| 2026-02-10 | Mr. Michael A. MarksCFO & Exec. VP | -1,69k | 848,46k | Sale to Issuer | 502,05 | 73,08k | -2,26% |
| 2026-02-10 | Mr. Samuel N. HazenCEO & Director | -21,32k | 10,71M | Sale to Issuer | 502,05 | 1,38M | -1,52% |
| 2026-02-10 | Mr. Jon Mack FosterExec. VP & COO | -5,89k | 2,96M | Sale to Issuer | 502,05 | 194,52k | -2,94% |
| 2026-02-10 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -3,50k | 1,76M | Sale to Issuer | 502,05 | 32,08k | -9,84% |
| 2026-02-11 | Ms. Jennifer L. BerresSenior VP & Chief HR Officer | -8,02k | 4,13M | Vente | 503,00 - 526,16 | 11,99k | -40,07% |
| 2026-02-10 | Ms. Jennifer L. BerresSenior VP & Chief HR Officer | -2,52k | 1,26M | Sale to Issuer | 502,05 | 11,99k | -17,34% |
| 2026-02-06 | Hercules Holding Ii, LLCSociété | -36,63M | 0,00 | Other Disposition | - | 32,28M | -53,15% |
| 2026-02-06 | Frisco Holding IISociété | -36,63M | 0,00 | Other Disposition | - | - | - |
| 2026-02-05 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | 5,00k | 694,74k | Derivative Exercise and Retained Stock | 139,06 | 46,06k | 12,17% |
| 2026-02-05 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -5,67k | 2,13M | Derivative Exercise and Sale | 139,06 - 513,76 | 46,06k | - |
| 2026-02-05 | Mr. Jon Mack FosterExec. VP & COO | 13,25k | 1,84M | Derivative Exercise and Retained Stock | 139,06 | 184,71k | 7,73% |
| 2026-02-05 | Mr. Jon Mack FosterExec. VP & COO | -16,08k | 6,02M | Derivative Exercise and Sale | 139,06 - 513,76 | 184,71k | - |
| 2026-02-03 | Mr. Samuel N. HazenCEO & Director | -42,88k | 21,48M | Vente | 497,18 - 502,95 | 1,35M | -3,08% |
| 2026-02-04 | Mr. Samuel N. HazenCEO & Director | -1,05k | 520,78k | Other Disposition | 498,35 | 1,35M | -0,08% |
| 2026-02-03 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -1,50k | 747,14k | Vente | 498,09 | 25,95k | -5,46% |
| 2026-02-03 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -4,05k | 0,00 | Other Disposition | - | 25,95k | -13,50% |
| 2026-01-30 | Mr. Samuel N. HazenCEO & Director | 42,88k | 3,51M | Derivative Exercise and Retained Stock | 81,96 | 1,39M | 3,18% |
| 2026-01-30 | Mr. Samuel N. HazenCEO & Director | -41,48k | 16,85M | Derivative Exercise and Sale | 81,96 - 488,27 | 1,39M | - |
| 2025-11-14 | Mr. Samuel N. HazenCEO & Director | -14,83k | 0,00 | Other Disposition | - | 1,35M | -1,09% |
| 2025-11-03 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -13,17k | 3,01M | Derivative Exercise and Sale | 236,61 - 473,79 | 5,62k | - |
| 2025-11-03 | Mr. Michael A. MarksCFO & Exec. VP | -330,00 | 0,00 | Other Disposition | - | 69,74k | -0,47% |
| 2025-10-31 | Mr. Samuel N. HazenCEO & Director | 29,88k | 2,08M | Derivative Exercise and Retained Stock | 69,58 | 1,36M | 2,24% |
| 2025-10-31 | Mr. Samuel N. HazenCEO & Director | -28,17k | 10,99M | Derivative Exercise and Sale | 69,58 - 459,68 | 1,36M | - |
| 2025-09-04 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -10,92k | 2,63M | Derivative Exercise and Sale | 173,12 - 418,84 | 31,50k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
